Lisuride in Parkinson's disease. 4-year follow-up.
Lisuride at a mean daily dose of 3 mg was given to 48 patients with idiopathic Parkinson's disease. Twenty received lisuride alone (Group A) and 36 received lisuride + L-Dopa + peripheral decarboxylase inhibitors (Group B). Dropouts were due primarily to lack of efficacy in Group A patients and to mental side effects in Group B patients. The patients who remained in the study for the full 4 years showed distinct improvement, which was maintained. Group A patients did not have the on-off phenomenon or abnormal involuntary movements.
Giovannini
P
P
Department of Neurology, Instituto Neurologico C. Besta, Milan, Italy.
Scigliano
G
G
Piccolo
I
I
Soliveri
P
P
Suchy
I
I
Caraceni
T
T
D000328:Adult; D000368:Aged; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008090:Lisuride / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D013997:Time Factors
D004873:Ergolines; D007980:Levodopa; D008090:Lisuride